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Murray A. Mittleman, MD, DRPH,†§ Kenneth J. Mukamal, MD, MPH*
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Objectives This study examines whether obesity accelerates atherogenic progression or adverse outcomes after coronary
artery bypass graft (CABG) surgery.
Background Obesity is a major risk factor for developing coronary heart disease. Whether obesity accelerates disease pro-
gression after CABG is unclear.
Methods We examined how body mass index (BMI) related to atherosclerotic graft progression and a clinical composite
outcome of death, nonfatal myocardial infarction, stroke, CABG surgery, or angioplasty among 1,314 partici-
pants in the Post CABG trial. Participants who had undergone CABG surgery were randomly assigned in a 2  2
factorial design to warfarin versus placebo and aggressive low-density lipoprotein cholesterol (LDL-C) lowering
with lovastatin 40 to 80 mg/day (to achieve LDL-C of 60 to 85 mg/dl) versus moderate LDL-C lowering with lo-
vastatin 2.5 to 5 mg/day (to achieve LDL-C of 130 to 140 mg/dl). Angiographic progression was assessed by
coronary angiography at 4 to 5 years.
Results Higher BMI was associated with a higher likelihood of angiographic progression (p trend  0.003) after adjust-
ment for demographic factors, treatment assignment, smoking status, and years since CABG surgery, but not
with clinical events (p trend  0.81). In stratified analyses, higher BMI was associated with angiographic pro-
gression in the low-dose lovastatin group (p trend 0.001) but not in the high-dose group (p  0.03 for test for
interaction of BMI and statin treatment). In the high-dose lovastatin group, higher BMI appeared to be protective
against clinical events (p trend  0.06, test of interaction: 0.02).
Conclusions Higher BMI is strongly associated with atherogenic progression after CABG surgery. Aggressive statin therapy
may be protective against obesity-related acceleration of coronary heart disease. (J Am Coll Cardiol 2008;52:
620–5) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.05.021w
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abesity is a leading cause of preventable death, a growing
pidemic, and a major contributor to cardiovascular
isease risk and mortality in the U.S. (1– 6). Although
besity’s adverse effect on cardiovascular disease risk is
rom the *Division of General Medicine and Primary Care and †Cardiovascular
pidemiology Research Unit, Beth Israel Deaconess Medical Center and Harvard
edical School, Boston, Massachusetts; ‡Department of Medicine, Medical College
f Wisconsin, Milwaukee, Wisconsin; and the §Department of Epidemiology,
arvard School of Public Health, Boston, Massachusetts. The Post CABG (Coro-
ary Artery Bypass Graft) study was conducted and supported by the National Heart,
ung, and Blood Institute (NHLBI) in collaboration with the Post CABG Study
nvestigators. This article was prepared using a limited access dataset obtained by the
HLBI and does not necessarily reflect the opinions or views of the Post CABG
tudy or the NHLBI. The authors had full access to the data and take responsibility
or its integrity. All authors have read and agree to the article as written.c
Manuscript received December 3, 2007; revised manuscript received May 1, 2008,
ccepted May 20, 2008.ell established, it is less clear whether obesity predicts
dverse outcomes after coronary artery bypass graft (CABG)
urgery (7,8).
In addition to its association with traditional cardiovas-
ular factors such as diabetes, hypertension, and dyslipide-
ia, obesity leads to metabolic changes that precipitate an
therogenic milieu (9). Adipose tissue is a major producer of
roinflammatory cytokines and hormones and is thought to
nduce low-grade systemic inflammation that has been
mplicated in the pathogenesis of cardiovascular disease
10). Few studies have been able to examine the impact of
besity on atherogenic outcomes after CABG surgery,
owever. Earlier studies that examined the impact of obesity
fter CABG surgery have primarily focused on post-operative
omplications and short-term mortality (7,8,11,12). Studies
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August 19, 2008:620–5 Obesity and Prognosis After CABGn obesity’s effect on post-CABG mortality over the long
erm have produced conflicting results, with a few studies
uggesting a protective relationship but others showing no
ffect or higher mortality risk (13–15). Moreover, interpre-
ation of the previous literature has been complicated by the
ifferences in study design and ways in which body mass
ndex (BMI) has been categorized (7,8,11–15).
Over the past few decades, several medical therapies have
een shown to improve cardiac disease outcomes, including
mproved graft patency after CABG surgery (16). In par-
icular, growing evidence suggests that statins may improve
oronary artery disease outcomes, including CABG graft
atency, not only by improving lipid levels but also by
owering systemic inflammation (17,18). Given that obesity
s believed to confer adverse cardiovascular risk by inducing
ow-grade inflammation in addition to its other adverse
ffects on traditional cardiovascular risk factors, statins may
roduce a larger benefit in patients who are obese than in
hose who are normal weight.
In this context, we examined the relationship between
besity and progression of graft atherosclerosis and risk of
linical cardiovascular events among participants enrolled in
he Post CABG trial (16,19). This trial evaluated low-dose
arfarin versus placebo and aggressive versus moderate-level
reatment with lovastatin on graft progression in patients
ith patent coronary artery bypass grafts; the study’s original
esults demonstrated that aggressive lowering of low-density
ipoprotein cholesterol (LDL-C) reduced progression of
raft atherosclerosis and the risk of subsequent clinical
vents, whereas low-dose warfarin did not. Our second aim
as to examine whether aggressive lipid-lowering therapy
ould attenuate the potentially adverse impact of obesity.
ethods
tudy population and design. The Post CABG trial was a
ulticenter, double-blind, randomized, controlled trial of
articipants who had undergone CABG surgery recruited
rom the Montreal Heart Institute, Cedars-Sinai Medical
enter, the Cleveland Clinic, the University of Minnesota,
nd Baylor College of Medicine. To be eligible, participants
ad to have undergone CABG surgery 1 to 11 years before
ntry and be 21 to 74 years of age. Other inclusion criteria
ncluded the presence of 2 completely independent, patent
aphenous vein grafts in men or 1 in women; an LDL-C
evel between 130 and 175 mg/dl; plasma triglycerides
elow 300 mg/dl; and a left ventricular ejection fraction of
t least 30%. Participants were excluded if there was a high
ikelihood of revascularization or death in 5 years, unstable
ngina or myocardial infarction within 6 months before the
tart of the trial, severe angina, heart failure, and absolute
ontraindications to treatment with any of the study med-
cations. Patients who had a markedly positive exercise test,
efined as the presence of ST-segment depression greater than
.5 mm in at least 1 lead, were also re-evaluated for possible
xclusion from the study. A total of 1,351 patients were anrolled. All participants pro-
ided written informed consent.
Participants were randomly
ssigned in a 2  2 factorial
esign to 1 of 4 treatment
roups: aggressive LDL-C low-
ring with lovastatin 40 to 80
g/day to achieve an LDL-C of
0 to 85 mg/dl versus moderate
DL-C lowering with lovastatin
.5 to 5 mg/day to achieve an
DL-C of 130 to 140 mg/dl and warfarin 1 to 4 mg/day to
chieve an international normalized ratio of 1.8 to 2.0 versus
lacebo. Participants could receive cholestyramine 8 mg/day
s necessary to achieve LDL-C goals. All participants also
eceived instruction regarding a National Cholesterol Edu-
ation Program Step I diet and were offered programs on
xercise and smoking cessation.
xposure assessment. Study staff measured the weight and
eight of all participants at baseline and recorded BMI as
he ratio of the weight in kilograms to the square of the
eight in meters. We categorized participants into 4 BMI
ategories according to National Institutes of Health guide-
ines: normal weight (18.5 to 24.9 kg/m2), overweight (25.0
o 29.9 kg/m2), class I obesity (30.0 to 34.9 kg/m2), and
lass II to III (35 kg/m2) (20). To minimize the bias
elated to underweight, we excluded the 37 participants with
BMI 18.5 kg/m2 or who had a history of cancer or
evere pulmonary disease.
utcome measurements. Participants were followed for
p to 5 years. Angiography was performed at baseline and at
to 5 years after enrollment. The primary end point of the
rial was atherosclerotic graft progression assessed by an-
iography 4 to 5 years after enrollment. The definition of
raft worsening in the Post CABG trial was a decrease of
0.6 mm in lumen diameter at the site of greatest change
t follow-up. As in previous Post CABG trial publications
21), all initially patent grafts were considered to have
eveloped graft worsening in patients who died prior to
epeat angiography.
In addition, participants were followed for clinical
vents through the end of the trial. The pre-defined
rincipal clinical end point was a composite clinical outcome
ncluding death from cardiovascular or unknown causes,
onfatal myocardial infarction, stroke, CABG surgery, or
ngioplasty.
ther covariates. At baseline, participants were assessed
or left ventricular function by angiography. Lipids were
easured in all participants at the individual clinical centers
sing the Lipid Research Clinics Program protocol (22).
articipants reported their smoking history, which we
eparated into 3 categories (never, former, and current).
nrolling centers recorded participants’ medical histories,
ncluding cardiovascular risk factors and previous clinical
iagnoses. Finally, limited physical activity information was
Abbreviations
and Acronyms
BMI  body mass index
CABG  coronary artery
bypass graft
CHD  coronary heart
disease
LDL-C  low-density
lipoprotein cholesterollso assessed. All participants reported 3 indicators of their
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Obesity and Prognosis After CABG August 19, 2008:620–5hysical activity: how their activity level compared with that
f others of the same age and sex at baseline in 5 categories
much more active to much less active), whether they
ngaged in strenuous exercise or labor, and whether they
xercised for 20 min at least 3 times a week.
tatistical methods. We prospectively evaluated the rela-
ionship between BMI and 2 measures of prognosis: the risk
f progression of graft atherosclerosis and the risk of
ecurrent coronary heart disease (CHD) events.
As in previous analyses from the Post CABG Trial
nvestigators, we analyzed graft progression on a per-graft
asis, using generalized estimating equations to account for
he clustering of grafts within participants (21). In these
nalyses, the primary outcome was a binary decrease of0.6
m in lumen diameter. We used a logit link to estimate
dds ratios and an exchangeable correlation matrix.
In analyses of CHD events using the pre-defined clinical
nd point, we used Cox proportional hazards models,
ensored at the date of first clinical event, death, or the end
f follow-up. Accordingly, we present hazard ratios with
heir 95% confidence intervals. Analysis of time-varying
ovariates demonstrated no violation of the proportional
azards assumption.
For both end points, we created initial models (model 1)
hat adjusted for age, gender, race, treatment assignment,
moking, and years since CABG surgery. We then devel-
ped additional models that further controlled for factors
hat might be in the causal pathway between obesity and
nd points of interest, including physical activity level
model 2) and clinical factors such as left ventricular ejection
aseline Characteristics of Post-CABG Participants According to B
Table 1 Baseline Characteristics of Post-CABG Participants Ac
18.5 to 24.9 (n  336) 25.0 t
Median BMI (kg/m2) 23.7
Age (yrs), mean (SD) 61.9 (7.4)
Years since CABG 4.7 (2.5)
Male gender, n (%) 300 (89)
White race, n (%) 304 (90)
Smoking status, n (%)
Current smoker 42 (13)
Former smoker 191 (57)
Alcohol abstainer, n (%) 179 (53)
Baseline clinical status
Diabetes, n (%) 14 (4)
Hypertension, n (%) 90 (27)
Previous MI, n (%) 169 (50)
LVEF (%), mean (SD) 58.8 (11.9)
Baseline laboratory results, mean (SD)
ALT, IU/l 20.8 (9.6)
WBC, K/ul 6.3 (1.7)
Triglycerides, mg/dl 140 (65)
HDL-C, mg/dl 42.4 (10.9)
LDL-C, mg/dl 158.3 (20.3)
he p values were derived from exact tests for categorical variables and analysis of variance for c
ALT  alanine aminotransferase; BMI  body mass index; CABG  coronary artery bypass graft; HDL-
entricular ejection fraction; MI  myocardial infarction; WBC  white blood cell.raction and prior history of hypertension, diabetes, myo-
ardial infarction, and stroke. For tests of trend, we tested
og (BMI) as a continuous measure after confirming the
ssumption of linearity within each BMI category; log
BMI) gave a better model fit than untransformed BMI
ith less sensitivity to outliers. To examine whether the
ffect of BMI varied with aggressive treatment of lipids with
ovastatin, we tested for a potential interaction between
andomized treatment assignment and log (BMI); we also
ested for an interaction between baseline lipid level and
og (BMI).
We used SAS System for Windows, release 9.1 (SAS
nstitute, Inc., Cary, North Carolina) for all analyses.
esults
ample characteristics. A total of 1,314 Post CABG trial
articipants were included in our analysis, of whom 198 had
clinical event. A total of 870 of 2,603 grafts showed
ignificant atherosclerotic progression during the course of
ollow-up. Table 1 shows the characteristics of study par-
icipants according to BMI category. Participants with
igher BMI were generally younger and exhibited a more
dverse cardiovascular risk factor profile.
MI and prognosis. Table 2 shows the likelihood of
linical events and angiographic end points stratified by
MI among Post CABG trial participants. After adjust-
ent for demographic factors, treatment assignment, smok-
ng status, and years since CABG surgery, BMI was not
ng to BMI
BMI (kg/m2)
p Value(n  656) 30.0 to 34.9 (n  254) 35.0 (n  68)
.1 31.7 37.5
(7.2) 60.3 (7.5) 60.2 (7.4) 0.02
(2.6) 4.9 (2.5) 5.0 (2.4) 0.72
(95) 238 (94) 57 (84) 0.001
(96) 239 (94) 64 (94) 0.003
(11) 21 (8) 8 (12) 0.41
(63) 180 (71) 49 (72) 0.002
(55) 152 (60) 47 (69) 0.05
(7) 23 (9) 9 (13) 0.02
(34) 117 (46) 36 (53) 0.001
(49) 127 (50) 29 (43) 0.70
(12.2) 56.8 (11.9) 55.5 (10.1) 0.002
(10.6) 25.6 (12.4) 28.3 (12.6) 0.001
(1.7) 6.8 (1.8) 7.6 (2.6) 0.001
(68) 182 (84) 200 (90) 0.001
(9.7) 37.4 (8.2) 37.5 (7.8) 0.001
(19.8) 158.7 (21.8) 163.2 (22.1) 0.31
us variables.MI
cordi
o 29.9
27
61.7
4.9
624
632
72
413
358
48
221
321
55.7
22.4
6.5
163
39.8
158.3
ontinuo
C  high-density-lipoprotein cholesterol; LDL-C  low-density-lipoprotein cholesterol; LVEF  left
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August 19, 2008:620–5 Obesity and Prognosis After CABGssociated with incident clinical events but was associated
ith angiographic progression.
odifying effects of aggressive lipid lowering. Table 3
hows the relationships between BMI and angiographic end
oints and clinical events stratified by randomized treatment
ssignment. In the low-dose lovastatin group, higher BMI
as associated with a higher odds ratio of angiographic
rogression and a higher hazard ratio of clinical events. In
he high-dose lovastatin group, BMI was not clearly asso-
iated with adverse outcome and appeared to be protective
gainst adverse clinical events. Tests for the interaction
etween BMI and lovastatin treatment groups on both
ngiographic and clinical end points were statistically sig-
ificant in our primary models (model 1) (p  0.03 and
.02, respectively). We did not detect a significant interac-
ion between baseline lipid level and BMI. Additional
djustment for measures of physical activity and clinical
actors had little effect on the point estimates.
iscussion
ummary of findings. In this population of patients who
nderwent CABG surgery and who were randomized to
ither high- or low-dose lovastatin, higher BMI was asso-
iated with a higher likelihood of atherosclerotic progres-
ion of CABG grafts but not with a higher likelihood of
linical cardiac events. However, even though higher BMI
as associated with the likelihood of angiographic progres-
ion and clinical events among those randomized to the
ow-dose lovastatin group, BMI was not clearly associated
ith adverse outcomes among those in the high-dose
ovastatin group and may be protective against clinical
ardiovascular events.
besity and outcomes in established coronary disease.
lthough there is strong evidence to suggest that obesity is
major risk factor for developing CHD, it is less clear
hether obesity accelerates progression of disease among
HR for Cardiovascular Events and OR forAngi graphic Findings According to Baseline BM
Table 2 HR for Cardiovascular Events and OAngiographic Findings According to
18.5 to 24.9
Clinical events
Participants (n) 336
Death or MI (n) 33 (10)
Composite events (n) 52 (15)
HR* 1.00
95% CI
Angiographic significant worsening
Grafts (n) 652
Significant worsening (n) 205 (31)
OR* 1.00
95% CI
*Model adjusts for age, gender, race, treatment assignment, smokin
severe chronic obstructive pulmonary disease excluded. Test for trend
CI  confidence interval; HR  hazard ratio; OR  odds ratio; othehose with existing coronary disease (7–15). An obesity iaradox has been observed in several clinical populations
ith cardiovascular and other diseases, in which greater
MI has been linked to better subsequent prognosis (23–
8). It seems likely that this paradox is related, at least in
art, to difficulty in fully accounting for weight loss related
o clinical comorbidity or severity of illness (29), particularly
uring short-term follow-up. Previous studies of adiposity
nd BMI and longer-term outcomes after CABG surgery
ave shown mixed results (7,13–15). Gurm et al. (15) used
ata collected as part of the BARI (Bypass Angioplasty
evascularization Investigation) study and found that obe-
ity was associated with a much higher 5-year risk of cardiac
ortality. In contrast, Kim et al. (7) did not find differences
n mortality across BMI at 30 days, 1 year, or 5 years after
ABG.
Our study is unique in being able to examine the
elationship between obesity and the more immediate end
oint of atherogenic graft progression, highlighting the
lear risk of obesity with greater progression of atheroscle-
osis over time. As in many previous studies, we found no
trong relationship between BMI and coronary events in the
verall study sample. However, given the established rela-
ionship of atherosclerotic progression with long-term clin-
cal events (30), obesity may well have led to a demonstrably
reater risk of clinical events with longer follow-up.
tatin treatment on obesity’s effect on cardiovascular end
oints. Our study also found important interactions be-
ween BMI and lovastatin treatment assignment for both
therogenic progression and clinical events. Among partic-
pants randomized to the low-dose lovastatin group, higher
MI was strongly associated with atherogenic progression
nd a trend toward a higher risk of clinical events. In
ontrast, higher BMI was not associated with atherogenic
raft progression among those assigned to high-dose lova-
tatin; moreover, high-dose lovastatin appeared to have a
reater protective effect on clinical end points. These find-
er CABG
line BMI After CABG
BMI (kg/m2)
p for Trendo 29.9 30.0 to 34.9 35.0
6 254 68
(9) 27 (11) 6 (9)
(16) 33 (13) 9 (13)
0.97 0.81 0.79 0.81
1.36 0.52–1.27 0.39–1.62
3 487 131
(32) 186 (38) 46 (35)
1.01 1.36 1.29 0.003
1.29 1.00–1.84 0.81–2.07
ears since CABG surgery. A BMI 18.5 kg/m2, history of cancer, or
MI as a continuous variable.
iations as in Table 1.I Aft
R for
Base
25.0 t
65
59
104
0.69–
1,33
433
0.79–
g, and yngs suggest that the adverse atherogenic effects conferred
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Obesity and Prognosis After CABG August 19, 2008:620–5y obesity may be ameliorated by aggressive treatment with
ovastatin. Whether this is a class effect of statins is not
lear; however, statins have been shown to not only improve
yslipidemia but also reduce systemic inflammation that
ight lead to atherosclerosis (16).
Current guidelines already recommend statin treatment in
atients with pre-existing coronary disease. Our findings rein-
orce its aggressive use in such patients who are also obese.
hether this added benefit in obesity is directly related to
ipid-lowering or anti-inflammatory effects of statins warrants
urther study. Future research should also examine whether the
tronger effect of statins in obese patients generalizes to
atients without pre-existing coronary disease, as these find-
ngs could have important implications on whether thresholds
or statin treatment should be lowered for patients with obesity.
Finally, our study suggests that once lipids are lowered,
besity may actually be protective against cardiovascular
isease. Future studies will need to confirm our findings and
HR for Cardiovascular Events and OR for Angiog(and 95% CI) Among Post-CABG Participants Ac
Table 3 HR for Cardiovascular Events and O(and 95% CI) Among Post-CABG Pa
18.5 to 24.9
Composite clinical events
Low-dose lovastatin, HR (95% CI)
Model 1 1.00
Model 2 1.00
Model 3 1.00
High-dose lovastatin, HR (95% CI)
Model 1 1.00
Model 2 1.00
Model 3 1.00
Angiographic significant worsening
Low-dose lovastatin, OR (95% CI)
Model 1 1.00
Model 2 1.00
Model 3 1.00
High-dose lovastatin, OR (95% CI)
Model 1 1.00
Model 2 1.00
Model 3 1.00
Model 1 adjusts for age, gender, race, treatment assignment, smoking
additionally adjusts for activity relative to others and frequency of str
adjusts for LVEF and past history of hypertension, diabetes, MI, and s
pulmonary disease excluded. Test for trend uses BMI as a continuous
Abbreviations as in Tables 1 and 2.xplore potential underlying mechanisms. ftudy strengths and limitations. The Post CABG trial
as large and based in multiple centers, and the assessment
f graft progression was uniform and systematic, an impor-
ant strength. The trial included both angiographic and
linical end points, and objective measurements of BMI.
ipid-lowering treatment was randomly assigned, allowing
s to evaluate the interaction of BMI with statin treatment
ree of confounding. However, clinical trial participants may
ractice healthier behaviors than other patients, and the trial
redominately enrolled white men, both potentially limiting
he generalizability of our study. Even though BMI was
easured in the trial, it was measured only at baseline and
s only one surrogate measure of adiposity; we were not able
o measure changes in weight over time, which may have
ad an impact on our outcome, although weight change
ould be systematically different between those randomized
o one treatment group compared with those in another
roup. Finally, there are few clinical events during the
c Progressioning t BMI a d Statin Treatment
Angiographic Progression
ants According to BMI and Statin Treatment
BMI (kg/m2)
p for Trendo 29.9 30.0 to 34.9 35.0
45 1.09 1.89 0.14
2.35) (0.59–2.02) (0.75–4.77)
46 1.11 1.55 0.23
2.39) (0.59–2.07) (0.59–4.05)
43 1.14 1.63 0.20
2.35) (0.61–2.14) (0.61–4.33)
60 0.58 0.30 0.06
0.98) (0.30–1.10) (0.09–1.00)
58 0.52 0.26 0.03
0.94) (0.27–1.01) (0.08–0.88)
54 0.47 0.25 0.02
0.90) (0.24–0.92) (0.07–0.86)
07 1.40 3.55 0.001
1.51) (0.93–2.10) (1.79–7.06)
04 1.32 2.81 0.001
1.49) (0.87–2.00) (1.42–5.53)
01 1.34 2.97 0.001
1.46) (0.88–2.05) (1.50–5.88)
95 1.31 0.56 0.75
1.36) (0.84–2.05) (0.27–1.15)
95 1.30 0.56 0.71
1.37) (0.83–2.03) (0.27–1.18)
91 1.22 0.53 0.85
1.32) (0.77–1.93) (0.25–1.14)
ars since CABG surgery. Model 2 includes variables frommodel 1 and
exercise. Model 3 includes variables from model 2 and additionally
BMI 18.5 kg/m2, history of cancer, or severe chronic obstructive
e.raphicord
R for
rticip
25.0 t
1.
(0.89–
1.
(0.89–
1.
(0.87–
0.
(0.37–
0.
(0.35–
0.
(0.32–
1.
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1.
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0.
(0.66–
0.
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August 19, 2008:620–5 Obesity and Prognosis After CABGence, our conclusions related to clinical events must be
nterpreted with caution.
onclusions
n summary, among individuals with known CHD who had
ndergone previous CABG surgery, BMI was most strongly
ssociated with significant angiographic progression in graft
therosclerosis in patients who were treated with low-dose
ovastatin. Higher BMI was not associated with adverse
therogenic or clinical coronary end points in patients
reated with high-dose lovastatin, suggesting that aggressive
reatment with this and potentially with other statins may
everse the adverse effect of obesity on coronary artery
isease progression. Future studies should examine whether
he larger benefits of statins in obese persons generalize to
hose without pre-existing coronary disease.
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